Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Catherine R.
Catherine R. Ferenz, Belchertown, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110152243 | NOVEL THIENOPYRROLE COMPOUNDS - The invention provides a compound of Formula (I) | 06-23-2011 |
Catherine R. Kostlan, Saline, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20100113601 | METHOD FOR DECREASING SEBUM PRODUCTION - The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin. | 05-06-2010 |
Catherine R. Linsmeier, Larsen, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20090033044 | RIDE-HEIGHT CONTROL SYSTEM - In some embodiments, a land vehicle includes sensors that provide information relating to a ride height of the land vehicle. A processing circuit monitors data from the sensors and controls adjustment of one or more vehicle systems that affect the vehicle's ride height based on the data from the sensors. In some embodiments, the processing circuit controls a suspension system and can control the suspension system to have any of a multiplicity of height settings. In some embodiments, the processing circuit controls the ride height based on a user selection of a pre-configured ride height setting. In some embodiments, the processing circuit is configured to maintain a ride height of the vehicle at a consistent ride height when the suspension is unlocked after a load is removed where the suspension was locked after the load was added. | 02-05-2009 |
Catherine R. Petts, Shenley GB
| Patent application number | Description | Published |
|---|---|---|
| 20080275020 | PHARMACEUTICAL FORMULATION - The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability. | 11-06-2008 |